# US 2004/0072268 A1 · Methods for regulating BRCA1-BRCA2-containing complex activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072268 A1
- Document ID: US20040072268A1
- Status: Published application
- Kind: A1
- Application number: 10/634,574
- Filed: 2003-08-05
- Published: 2004-04-15
- Earliest claimed: 2002-08-05
- Inventors: Ramin Shiekhattar
- Web page: https://patentgrep.com/patent/US20040072268A1

## CPC

- G01N 33/57515: of the breast
- C12Q 1/25: involving enzymes not classifiable in groups C12Q1/26 {- C12Q1/66}
- C12Q 1/34: involving hydrolase
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/575: for cancer
- G01N 2333/9015: Ligases (6)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention relates to methods of regulating the activity of at least one component of the BRCA1-BRCA2-containing complex (BRCC) by providing agents which specifically interact with BRCC components BRCC36 or BRE or nucleic acid sequences encoding BRCC36 or BRE. Methods of identifying such agents and using them to treat cancer are also provided. BRCC activities altered by such agents include ubiquitin E3 ligase activity, ubiquitin hydrolase activity, DNA repair activity, and transcriptional regulator activity. BRCC36-specific antibodies and methods for diagnosing cancers associated with BRCC are also described.

## Claims

### Claim 1

A method for modulating the activity of at least one component of a BRCA1-BRCA2-containing complex (BRCC) comprising contacting a BRCC or cell containing a BRCC with an agent that interacts with a nucleic acid sequence encoding BRCC36 or BRE, or a product thereof, so that the expression or activity of BRCC36 or BRE is altered thereby modulating an activity of at least one component of a BRCC.

### Claim 2 (depends on 1)

The method of claim 1 wherein the at least one component of a BRCC comprises BRCA2, BRCA1, RAD51, BARD1, BRCC300, BRCC140, BRCC130, BRCA1 Δ11, BRCC80, BRE, or BRCC36.

### Claim 3 (depends on 1)

The method of claim 1 wherein the activity of the component comprises ubiquitin E3 ligase activity, ubiquitin hydrolase activity, DNA repair activity, or transcriptional regulator activity.

### Claim 4

A method for identifying an agent that modulates the ubiquitin E3 ligase activity or ubiquitin hydrolase activity of BRCC comprising contacting BRCC with a test agent and monitoring the ability of said agent to alter the level of ubiquitination of select protein which is indicative of ubiquitin E3 ligase activity or ubiquitin hydrolase activity of BRCC.

### Claim 5

A method for identifying an agent that modulates the DNA repair activity of BRCC comprising contacting a cell containing BRCC with a test agent and monitoring the ability of said agent to alter cell survival rates in the presence of ionizing radiation or alter homology-directed DNA repair which is indicative of DNA repair activity of BRCC.

### Claim 6

A method for identifying an agent that modulates the transcriptional regulator activity of BRCC comprising contacting a cell containing BRCC with a test agent and monitoring the ability of said agent to alter the expression of genes containing p53 response elements which is indicative of transcriptional regulator activity of BRCC.

### Claim 7 (depends on 4)

An agent identified by the method of claim 4.

### Claim 8 (depends on 5)

An agent identified by the method of claim 5.

### Claim 9 (depends on 6)

An agent identified by the method of claim 6.

### Claim 10 (depends on 4)

A method for treating a cancer associated with BRCC comprising administering to a patient having a cancer associated with BRCC an effective amount of an agent identified by the method of claim 4.

### Claim 11 (depends on 5)

A method for treating a cancer associated with BRCC comprising administering to a patient having a cancer associated with BRCC an effective amount of an agent identified by the method of claim 5.

### Claim 12 (depends on 6)

A method for treating a cancer associated with BRCC comprising administering to a patient having a cancer associated with BRCC an effective amount of an agent identified by the method of claim 6.

### Claim 13

A method for identifying an agent that inhibits the expression of BRCC36 or BRE protein comprising contacting a cell expressing BRCC36 or BRE protein with a test agent and monitoring the ability of said agent to alter the expression of BRCC36 or BRE protein.

### Claim 14 (depends on 13)

An agent identified by the method of claim 13.

### Claim 15 (depends on 14)

A method for treating a cancer associated with BRCC comprising administering to a patient having a cancer associated with BRCC an effective amount of an agent of claim 14.

### Claim 16

An antibody which specifically recognizes BRCC36 or BRE protein.

### Claim 17

A method for diagnosing a cancer or the risk of developing a cancer associated with BRCC comprising
detecting a level or sequence of a nucleic acid sequence encoding BRCC36 or BRE, or a product thereof, in sample;
comparing said level or sequence of a nucleic acid sequence encoding BRCC36 or BRE, or a product thereof in the sample to a level or sequence of a nucleic acid sequence encoding BRCC36 or BRE, or a product thereof, in a control;
wherein a change in the level or sequence of a nucleic acid sequence encoding BRCC36 or BRE, or a product thereof, in the sample as compared to the control is indicative of a cancer or the risk of developing a cancer associated with BRCC.
